Oppenheimer Maintains Outperform on Soleno Therapeutics, Raises Price Target to $65
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Soleno Therapeutics (NASDAQ:SLNO) and raises the price target from $59 to $65.
August 12, 2024 | 12:06 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer analyst Leland Gershell maintains an Outperform rating on Soleno Therapeutics and raises the price target from $59 to $65.
The raised price target and maintained Outperform rating from a reputable analyst at Oppenheimer is likely to positively impact investor sentiment and drive short-term price appreciation for Soleno Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100